"Research has shown that being inactive is one of the strongest predictors of disease progression and early death. That may ...
FDA approves Hibsago (bepirovirsen) with NrtI therapy for adult chronic hepatitis B without cirrhosis; phase 3 trials show up to 20% functional cure at 72 weeks.
Some adults with chronic hepatitis B may now have a path to something today's treatments rarely deliver—stopping all ...
Some adults with chronic hepatitis B may now have a path to something today's treatments rarely deliver - stopping all ...
GDF15 may protect against alcohol-associated liver disease by suppressing neutrophil glycolysis, inflammation, and liver ...
A fire destroyed a Westmoreland County home, leaving Russell and AnnaJean Buckholz along with their children homeless as they ...
(Nasdaq: GILD) will present new clinical and real-world evidence across primary biliary cholangitis (PBC) and chronic ...
The FDA approved Hibsago (bepirovirsen) from GSK, the first antisense oligonucleotide for chronic hepatitis B in adults ...
YAQ001 associated with favorable shifts in gut microbial species and lower abundance of virulence and antibiotic resistance genesTrends toward improved markers of gut permeability and systemic ...
A rare inherited change in a single gene may directly cause fatty liver disease in some people, even when they lack familiar ...
For the first time, many people living with chronic hepatitis B may have a functional cure at hand. The US Food and Drug ...
Hibsago, the first FDA-approved antisense oligonucleotide to treat chronic hepatitis B, reduces the amount of virus and hepatitis B surface antigen in the body.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results